Tag: Atomoxetine

According to 2022 data from the CDC, over 7 million U.S. children aged 3–17 have been diagnosed with ADHD. Atomoxetine is a non-stimulant medication primarily used to answer the question: **what is atomoxetine used for?** It's a key treatment for Attention-Deficit/Hyperactivity Disorder (ADHD).

Over 6 million children in the U.S. have been diagnosed with ADHD, a condition impacting attention and behavior. In the realm of non-stimulant treatments for ADHD, a prominent answer to what is an example of a NaRI drug is atomoxetine, also known by the brand name Strattera.

Studies show that between 18.6% and 53.3% of individuals with ADHD also suffer from depression, making questions about medication combinations common [1.6.3]. So, can you take Strattera and Celexa together? The answer requires a careful look at the risks.

In 2023, over 3 million prescriptions for atomoxetine (Strattera) were filled in the United States [1.5.4]. For many adults starting this non-stimulant ADHD medication, a primary concern is: **Does Strattera cause constipation?** Yes, it is a common side effect, particularly in adults [1.2.1, 1.10.5].

In the United States, an estimated 6% of adults have a current ADHD diagnosis, which translates to over 15 million people [1.10.2]. For many, medication is a key part of treatment. So, **how does Strattera affect the brain?** This non-stimulant drug works by selectively increasing levels of norepinephrine, a vital brain chemical, to enhance focus, attention, and impulse control [1.2.1, 1.2.2].

An estimated 3.4% of adults worldwide have ADHD, and for many, medication is a key part of treatment. While stimulants are often a first-line option, atomoxetine offers a unique approach for those who cannot tolerate or prefer an alternative treatment pathway. This article explores in detail what atomoxetine does for ADHD and how it impacts the brain.

Strattera, also known by its generic name atomoxetine, is a non-stimulant medication for Attention-Deficit/Hyperactivity Disorder (ADHD). Understanding **who should avoid Strattera** is crucial for ensuring patient safety.

According to a 2022 survey, over 7 million children in the U.S. have been diagnosed with ADHD [1.11.1]. For many, medication is a key part of treatment, but it's vital to understand all potential side effects. The question of *Can Strattera cause confusion?* is an important one for patients and caregivers to explore.

In 2023, Eli Lilly Canada officially discontinued the brand-name ADHD medication Strattera. The primary reason for this phase-out was the expiration of its patent, which opened the door for generic competition and resulted in the company ceasing production of the branded version.

Yes, atomoxetine is FDA-approved for the long-term (maintenance) treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents, and adults. This non-stimulant medication demonstrates maintained efficacy and a manageable safety profile during extended use, offering a valuable option for chronic ADHD management.